uniQure NV (QURE)

[chmcnfunds]

J. Goldman & Company Sells 142,073 Shares of Uniqure NV (QURE)

December 31st, 2015 - By Doug Madison - 0 comments

Uniqure NV logoJ. Goldman & Company decreased its position in Uniqure NV (NASDAQ:QURE) by 83.6% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 27,874 shares of the company’s stock after selling 142,073 shares during the period. J. Goldman & Company owned 0.13% of Uniqure NV worth $570,000 at the end of the most recent reporting period.

Shares of Uniqure NV (NASDAQ:QURE) opened at 16.12 on Thursday. The firm’s market cap is $390.39 million. The firm has a 50-day moving average price of $18.11 and a 200-day moving average price of $23.17. Uniqure NV has a 52 week low of $14.67 and a 52 week high of $36.38.

Uniqure NV (NASDAQ:QURE) last issued its earnings results on Monday, November 30th. The company reported ($1.14) earnings per share for the quarter, missing the consensus estimate of ($0.64) by $0.50. On average, equities research analysts predict that Uniqure NV will post ($3.03) earnings per share for the current year.

A number of equities analysts have recently issued reports on the company. Roth Capital restated a “buy” rating and set a $38.00 price objective on shares of Uniqure NV in a research report on Monday, September 21st. Piper Jaffray reiterated a “buy” rating on shares of Uniqure NV in a report on Monday, September 21st. Oppenheimer lifted their target price on Uniqure NV from $47.00 to $50.00 and gave the stock an “outperform” rating in a report on Monday, September 21st. Leerink Swann reiterated an “outperform” rating and issued a $48.00 target price (up from $44.00) on shares of Uniqure NV in a report on Monday, September 21st. Finally, Chardan Capital reiterated a “buy” rating on shares of Uniqure NV in a report on Wednesday, September 16th. One research analyst has rated the stock with a hold rating and eleven have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $41.36.

Uniqure NV is a pharmaceutical company based in the Netherlands. It is primarily engaged in the field of gene therapy for orphan diseases. The Company is focused on patients suffering from genetic or acquired diseases by directing the expression of a therapeutic protein or restoring the expression of a missing protein through a single administration. The Company’s first product is Glybera, for the treatment of lipoprotein lipase deficiency (NASDAQ:QURE). In the clinical pipeline, it has gene treatments for hemophilia, porphyria, Parkinson, Sanfilippo B syndrome and hearing loss. Additionally, it is engaged in the development of therapies based on adeno-associated virus (AAV) through multiple collaborations. The Company uses modular technology platform, including a cost effective manufacturing process. In August 2014, Uniqure NV acquired InoCard GmbH, an early-stage biotechnology company focused on the development of gene therapy approaches for cardiac disease.
_________________________________________________-
http://www.dakotafinancialnews.com/j-goldman-company-sells-142073-shares-of-uniqure-nv-qure/774360/

So what is it? Buys or sells? Need to check but don't see proof of either yet.

QURE